LDHA · GalNAc, SC
Nedosiran (Rivfloza)
An approved siRNA therapeutic silencing LDHA, indicated for Primary hyperoxaluria type 1. This page lists what the siRNA Atlas corpus holds on Nedosiran and links to each primary document.
Identity
- Generic name
- Nedosiran
- Brand name
- Rivfloza
- Molecular target
- LDHA
- Indication
- Primary hyperoxaluria type 1
- Delivery
- GalNAc, SC
- FDA application
- NDA 215842
- Regulatory coverage
- FDA only
Source documents in the corpus (2)
Every answer about Nedosiran is drawn from these documents and the indexed literature, and cites the passage it used. Tables inside them are preserved, so numeric dosing, exposure and toxicology values stay searchable.
Ask the corpus about Nedosiran
- →What is the approved dose and dosing interval of nedosiran (Rivfloza)?
- →Describe the clinical pharmacology and ADME of nedosiran.
- →What did the regulatory reviews conclude about the nonclinical safety of nedosiran?
- →Summarise the pivotal trial evidence for nedosiran.
- →How does nedosiran silence LDHA, and how long does the effect last?
Other approved siRNA therapeutics
Information here is drawn from public regulatory records for reference and research. It is not medical advice — verify any clinical or regulatory decision against the current label and assessment report linked above.